Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy

被引：7

作者：

Woell, Ewald ^{[1
]}

Eisterer, Wolfgang ^{[2
]}

Gerger, Armin ^{[3
]}

Kuehr, Thomas ^{[4
]}

Prager, Gerald W. ^{[5
]}

Rumpold, Holger ^{[6
]}

Ulrich-Pur, Herbert ^{[7
]}

Vogl, Ursula ^{[8
]}

Winder, Thomas ^{[6
]}

Weiss, Lukas ^{[9
]}

Greil, Richard ^{[9
]}

机构：

[1] St Vinzenz Hosp, Dept Internal Med, Zams, Austria

[2] Klagenfurt Hosp, Dept Internal Med & Oncol, Klagenfurt, Austria

[3] Med Univ Graz, Div Clin Oncol, Dept Internal Med, Graz, Austria

[4] Wels Grieskirchen Hosp, Dept Internal Med 4, Wels, Austria

[5] Med Univ Vienna, Dept Med 1, Vienna, Austria

[6] Acad Teaching Hosp Feldkirch, Dept Internal Med 2, Feldkirch, Austria

[7] Wilhelminenspital Stadt Wien, Dept Internal Med 1, Vienna, Austria

[8] Barmherzige Schwestern Hosp, Dept Internal Med 1, Vienna, Austria

[9] Paracelsus Med Univ Salzburg, Med Dept Haematol Med Oncol Haemostaseol Infect D, Oncol Ctr, Salzburg, Austria

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 09期

关键词：

Gastric cancer; adenocarcinoma; stomach; lower gastroesophageal junction; treatment algorithm; review; RANDOMIZED PHASE-III; OPEN-LABEL; PERIOPERATIVE CHEMOTHERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; CANCER; MULTICENTER; DOCETAXEL; PLUS; CHEMORADIOTHERAPY;

D O I：

10.21873/anticanres.13638

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite recent advances in the treatment of gastric cancer, mortality related to this disease is still substantial. Surgery and chemotherapy represent the cornerstones of patient management. Targeted treatments that include anti-angiogenic agents and the advent of immunotherapies can contribute to improved patient prognosis. Herein, we present an Austrian consensus on the systemic treatment of patients with gastric adenocarcinoma and lower gastroesophageal junction, including those with human epidermal growth factor receptor 2 (HER2)-positive disease. The consensus considers the curative setting, as well as first-line to late-line systemic treatment options in the palliative setting. For HER2-positive disease, first-line and second-line therapies are discussed, as well as HER2 testing. Potential future therapies are also listed, with a focus on anti-angiogenic treatments and checkpoint inhibition, that might provide a further step forward in the management of patients with gastric cancer.

引用

页码：4589 / 4596

页数：8

共 43 条

[21] Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Kang, Yoon-Koo ;

Boku, Narikazu ;

Satoh, Taroh ;

Ryu, Min-Hee ;

Chao, Yee ;

Kato, Ken ;

Chung, Hyun Cheol ;

Chen, Jen-Shi ;

Muro, Kei ;

Kang, Won Ki ;

Yeh, Kun-Huei ;

Yoshikawa, Takaki ;

Oh, Sang Cheul ;

Bai, Li-Yuan ;

Tamura, Takao ;

Lee, Keun-Wook ;

Hamamoto, Yasuo ;

Kim, Jong Gwang ;

Chin, Keisho ;

Oh, Do-Youn ;

Minashi, Keiko ;

Cho, Jae Yong ;

Tsuda, Masahiro ;

Chen, Li-Tzong .

LANCET, 2017, 390 (10111) :2461-2471

[22] Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer [J].

Kim, Seung Tae ;

Cristescu, Razvan ;

Bass, Adam J. ;

Kim, Kyoung-Mee ;

Odegaard, Justin, I ;

Kim, Kyung ;

Liu, Xiao Qiao ;

Sher, Xinwei ;

Jung, Hun ;

Lee, Mijin ;

Lee, Sujin ;

Park, Se Hoon ;

Park, Joon Oh ;

Park, Young Suk ;

Lim, Ho Yeong ;

Lee, Hyuk ;

Choi, Mingew ;

Talasaz, Amirali ;

Kang, Peter Soonmo ;

Cheng, Jonathan ;

Loboda, Andrey ;

Lee, Jeeyun ;

Kang, Won Ki .

NATURE MEDICINE, 2018, 24 (09) :1449-+

[23]

Lordick F, 2018, Onkopedia leitlinien magenkarzinom

[24] Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer [J].

Lorenzen, S. ;

Pauligk, C. ;

Homann, N. ;

Schmalenberg, H. ;

Jaeger, E. ;

Al-Batran, S-E .

BRITISH JOURNAL OF CANCER, 2013, 108 (03) :519-526

[25] Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. [J].

Macdonald, JS ;

Smalley, SR ;

Benedetti, J ;

Hundahl, SA ;

Estes, NC ;

Stemmermann, GN ;

Haller, DG ;

Ajani, JA ;

Gunderson, LL ;

Jessup, JM ;

Martenson, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (10) :725-730

[26]

MAKIYAMA A, 2018, J CLIN ONCOL S, V36

[27] German S3-Guideline "Diagnosis and Treatment of Esophagogastric Cancer" [J].

Moehler, M. ;

Al-Batran, S. -E. ;

Andus, T. ;

Anthuber, M. ;

Arends, J. ;

Arnold, D. ;

Aust, D. ;

Baier, P. ;

Baretton, G. ;

Bernhardt, J. ;

Boeing, H. ;

Boehle, E. ;

Bokemeyer, C. ;

Bornschein, J. ;

Budach, W. ;

Burmester, E. ;

Caca, K. ;

Diemer, W. A. ;

Dietrich, C. F. ;

Ebert, M. ;

Eickhoff, A. ;

Ell, C. ;

Fahlke, J. ;

Feussner, H. ;

Fietkau, R. ;

Fischbach, W. ;

Fleig, W. ;

Flentje, M. ;

Gabbert, H. E. ;

Galle, P. R. ;

Geissler, M. ;

Gockel, I. ;

Graeven, U. ;

Grenacher, L. ;

Gross, S. ;

Hartmann, J. T. ;

Heike, M. ;

Heinemann, V. ;

Herbst, B. ;

Herrmann, T. ;

Hoecht, S. ;

Hofheinz, R. D. ;

Hoefler, H. ;

Hoehler, T. ;

Hoelscher, A. H. ;

Horneber, M. ;

Huebner, J. ;

Izbicki, J. R. ;

Jakobs, R. ;

Jenssen, C. .

ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2011, 49 (04) :461-531

[28] Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses [J].

Park, Se Hoon ;

Sohn, Tae Sung ;

Lee, Jeeyun ;

Lim, Do Hoon ;

Hong, Min Eui ;

Kim, Kyoung-Mee ;

Sohn, Insuk ;

Jung, Sin Ho ;

Choi, Min Gew ;

Lee, Jun Ho ;

Bae, Jae Moon ;

Kim, Sung ;

Kim, Seung Tae ;

Park, Joon Oh ;

Park, Young Suk ;

Lim, Ho Yeong ;

Kang, Won Ki .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) :3130-+

[29] Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604) [J].

Saeki, Hiroshi ;

Oki, Eiji ;

Kashiwada, Tomomi ;

Arigami, Takaaki ;

Makiyama, Akitaka ;

Iwatsuki, Masaaki ;

Narita, Yukiya ;

Satake, Hironaga ;

Matsuda, Yoshiko ;

Sonoda, Hideto ;

Shimokawa, Mototsugu ;

Maehara, Yoshihiko .

EUROPEAN JOURNAL OF CANCER, 2018, 105 :41-49

[30] Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) [J].

Seo, Seyoung ;

Ryu, Min-Hee ;

Park, Young Soo ;

Ahn, Ji Yong ;

Park, Yangsoon ;

Park, Sook Ryun ;

Ryoo, Baek-Yeol ;

Lee, Gin Hyug ;

Jung, Hwoon-Young ;

Kang, Yoon-Koo .

GASTRIC CANCER, 2019, 22 (03) :527-535

← 1 2 3 4 5 →